Keywords drug interactions, drug-related side effects, fusidic acid, rhabdomyolysis, statin Following a severe case of rhabdomyolysis in our University Hospital after a co-administration of atorvastatin and fusidic acid, we describe this interaction as this combination is not clearly contraindicated in some countries, particularly for longterm treatment by fusidic acid. All cases of rhabdomyolysis during a co-administration of a statin and fusidic acid were identified in the literature and in the World and Health Organization database, VigiBase ® . In the literature, 29 cases of rhabdomyolysis were identified; mean age was 66 years, median duration of co-administration before rhabdomyolysis occurrence was 21 days, 28% of cases were fatal. In the VigiBase ® , 182 cases were retrieved; mean age was 68 years, median duration of co-administration before rhabdomyolysis was 31 days and 24% of cases were fatal. Owing to the high fatality associated with this co-administration and the long duration of treatment before rhabdomyolysis occurrence, fusidic acid should be used if there is no appropriate alternative, as long as statin therapy is interrupted for the duration of fusidic acid therapy, and perhaps a week longer. Rarely will interruption of this sort have adverse consequences for the patient.
Introduction
Hydroxymethylglutaryl coenzyme A reductase inhibitors, also called statins, are a lipid-lowering drug class discovered at the end of the 1980s and widely prescribed in primary and secondary prevention of cardiovascular diseases. Their main adverse effects are elevation in liver enzymes and muscular toxicity, from benign myalgia to myopathy (tenfold elevation in creatine kinase with muscle pain) and lifethreatening rhabdomyolysis [1] . Although the mechanism of this muscular toxicity has not yet been clearly elucidated, the risk of rhabdomyolysis in statin users can be exacerbated by several factors including medicines that alter statin metabolism and increase statin plasma concentration. Thompson et al. [2] reported that approximately 60% of cases of rhabdomyolysis under statin medication are associated with drugdrug interactions involving statin metabolism modification.
Systemic fusidic acid is an antibiotic used mainly in methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis. Its interaction with statins is known and mentioned in the summary of product characteristics (SPC) and leaflets of most statins in many countries [3] [4] [5] as well as in some classic drug references [6, 7] but not all [8] . The Food and Drug Administration (FDA) cautions about this interaction on its website, even if systemic fusidic acid is not currently marketed in the USA [9] . However, many prescribers remain unaware of this interaction; some agencies do not clearly contraindicate this combination [10, 11] and severe cases of muscular adverse effects related to the concomitant use of statins and systemic fusidic acid are still occurring. In our University Hospital, in February 2016, a severe case of rhabdomyolysis occurred in a 51-year-old man treated with atorvastatin, 80 mg once a day, to whom an antibiotic treatment by systemic fusidic acid (500 mg three times a day) and ofloxacin was prescribed for an osteitis. He started to have leg pain 33 days after the beginning of antibiotic treatment and one week after a stress test. Fusidic acid and ofloxacin were stopped. Myalgia and muscle weakness made walking impossible and the patient was hospitalized. During hospitalization, he presented with anuria with a serum creatinine peak at 630 μmol l À1 (normal range 62-106 μmol l À1 ), serum creatine kinase increased at 976 times the upper limit of normal (ULN), myoglobin was at 367 × ULN and ASAT at 47 × ULN. Atorvastatin was discontinued on Day 3 of hospitalization and the patient's condition improved after dialysis and nine days of hospitalization but with a sequelar amyotrophy of thighs. He was discharged without treatment by atorvastatin, nor any other statin. Following this severe case that can be viewed as fully preventable, we decided to review data from the literature and data of spontaneous reporting from the World Health Organization (WHO) Global Individual Case Safety Reports (ICSRs) database VigiBase ® in order to describe the clinical patterns and better define fusidic acid-statin interaction. This review only concerned events of rhabdomyolysis.
Methods

Literature data collection
Medline was searched using the MeSH terms (Medical Subject Headings) 'rhabdomyolysis', 'hydroxymethylglutaryl-CoA reductase inhibitors', or each individual statin names (atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin) and 'fusidic acid' until December 2016. Moreover, cases identified in the references of reviewed articles were retrieved and added when relevant. Characteristics of patients, implicated statin, statin dose, duration of statin-fusidic acid co-administration, highest measured serum creatine phosphokinase (CPK) level, event outcome and the duration of hospital stay were collected.
Vigibase
® data collection (Figure 1 ). In the UK, the peak of notification was in 2013 (n = 24); three cases occurred in 2013 (20 cases had a date of occurrence not mentioned and one case was retrospective among the 24 cases notified) and no new cases have been reported since then. In France, the peak of notification was in 2014 (n = 26) and between two and four cases occurred each year from 2012 to 2016 ( Figure S1 ). In the 182 case reports, the PT mostly associated with rhabdomyolysis were: drug interaction (35%), acute kidney injury (25%), blood creatine phosphokinase increase (16%), muscular weakness (12%), myalgia (12%) and myopathy (5%). Atorvastatin (52%) and simvastatin (40%) were the most frequently involved statins, followed by rosuvastatin (5%), pravastatin (3%) and fluvastatin (2%). In 27 cases (15%), fusidic acid was only mentioned as concomitant drug, while a statin was considered as suspected or interacting drug. Conversely, a statin was mentioned as concomitant drug in two cases (1%) where fusidic acid was suspected of the effect (Tables S1 and S2 ). Among the 182 cases, 149 (82%) were serious and one (1%) was not; seriousness was not documented for the 32 remaining cases (18%). For the 155 cases where the patient age was available, mean age was 68 years (range 46-92 years); 75% of patients were men. The median duration of coadministration based on the 78 cases where data were available was 31 days (range 0-642 days); in 74% of these cases, rhabdomyolysis occurred after more than 3 weeks of coadministration (Figure 2 ). At the time of reporting, the outcome was documented in 152 cases: 57 (37%) patients had fully recovered, 27 (18%) were recovering, 27 (18%) had not recovered, 4 (3%) had recovered with sequelae and 37 patients (24%) had died from the rhabdomyolysis.
Discussion
This review identified severe rhabdomyolysis associated with a high rate of mortality after co-administration of statin and fusidic acid. A total of 12 countries were concerned but two of them appear in the front line, the United Kingdom and France. The absence of reporting from some countries may result from the lack of availability of the concerned drugs or the existence of a fully effective contraindication resulting in an absence of concomitant use of the drugs. Surprisingly, 17 cases were reported in the USA where fusidic acid was not marketed [6, 32] .
Official recommendations associated with the coprescription of fusidic acid and statin differ greatly from country to country. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) informed in September 2011 of the risk of rhabdomyolysis due to interaction between systemic fusidic acid and statins and recommended not coprescribing both drugs [11] . Nevertheless, the combination is not strictly contraindicated. The SPC of most statins mentions that the combination with systemic formulations of fusidic acid must not be used but that 'in exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g. for the treatment of severe or deep-seated infections, the need for co-administration of statin and fusidic acid should be considered on a case by case basis and only under close medical supervision'. In France, the French Agency for Medicines and Health Products Safety (ANSM) modified its recommendations: the combination was not recommended in January 2016 and has been contraindicated since August 2016 [33] . In Australia, the co-administration of fusidic acid and statins is contraindicated for all statins, except for fluvastatin, where the combination could be considered in some exceptional circumstances, similar to those of the UK [34] .
After the UK warning in 2011, few cases occurred there according to the data issued from Vigibase ® and no cases have been reported since 2014. This may suggest that the warning was effective although this may also be related to a lack of appreciation of the interaction or the general tendency of clinicians to not report adverse drug reactions already reported or recognized. Nevertheless, the number of cases may be underestimated as the date of occurrence was not documented for many cases and the cases only refer to spontaneous notification. In France, despite communication by the French Agency in 2011 on its website [35] regarding statin and fusidic acid combination (contraindicated for skin infections, not recommended for osteo-articular infections) and strong warning in the summaries of product characteristics, cases continue to occur. Consequently, measures in France appeared insufficient to control the risk of rhabdomyolysis. Following the occurrence of new cases, the concomitant use of statin and fusidic acid was contraindicated in France in 2016, irrespective of the duration of fusidic acid treatment [33] . This decision was based on the current recommendations allowing statin treatment discontinuation of up to 6 months [36] and the duration of treatment by fusidic acid that generally does not exceed 6 months, even in deep osteo-articular infections. The present review is the largest case series to analyse more than 150 case reports to date. It includes cases issued from publications and Vigibase ® , which provides a greater robustness in the current results without a possible publication bias [37] . Here, cases from literature and Vigibase ® were quite similar; they concerned mainly atorvastatin and simvastatin, and could occur after a long duration of co-administration. No cases were reported or published with cerivastatin (withdrawn from the global market in 2001), lovastatin and pitavastatin. Nevertheless, it is difficult to draw firm conclusions on the basis of these elements, due to the lack of consumption data, different duration of use, different indications in different countries. Moreover, lovastatin is not available in the UK and France, the countries with the most reported cases; pitavastatin is not available in France and marketed in the UK only since 2010. One important point highlighted by both published cases and spontaneous reports is the peak of rhabdomyolysis that occurred between 3 weeks and 3 months of co-administration. Owing to this long delay before rhabdomyolysis occurrence, statins should not be used with fusidic acid when prolonged systemic fusidic acid is needed, as is the case for the treatment of severe infections such as osteo-articular infections. Interestingly, an interaction between the statin and fusidic acid may not have been suspected in some VigiBase ® cases. For healthcare practitioners not aware of this drug-drug interaction, this could be considered as simply a statin-induced rhabdomyolysis, in particular because this is a well-known ADR to the statin class of drugs that can occur at any time during treatment [20, 38] and that fusidic acid was introduced some weeks before.
Originally, the mechanism of the interaction between statins and fusidic acid was thought to be related to their hepatic metabolism through the cytochrome P450 3A4. Indeed, both atorvastatin and simvastatin undergo substantial metabolism by this cytochrome and fusidic acid was found to inhibit it, which would result in statin accumulation and risk of toxicity [39] [40] [41] . However, with the occurrence of cases with rosuvastatin and pravastatin, which are respectively slightly [42] and not metabolized [42] [43] [44] by CYP450, this hypothesis was not satisfactory to completely explain this interaction. Besides, classically enzyme inhibition of CYP450 occurs within days, resulting in the rapid development of toxicity, and not after weeks or months such as reported here [7] . Some anecdotal cases of interaction with a long delay of occurrence have been suspected between statins and some CYP3A4 inhibitor drugs, such as ticagrelor and cyclosporine [45, 46] . Nevertheless, to our knowledge, no other large series such as ours has been reported with such a long delay before occurrence. This seems unique to fusidic acid and provides a supplementary argument to suspect another mechanism.
To date, no clinical pharmacokinetic interaction studies with fusidic acid and statins have been conducted to understand the current interaction. However, in vitro studies highlighted an inhibition of CYP450 isoenzymes by fusidic acid [39] [40] [41] 47] but also others mechanisms [39, 47] that could lead to an increased statin bioavailability: (i) inhibition by fusidic acid of transport proteins such as organic anion transporting polypeptide (OATP), breast cancer resistance protein (BCRP), and multi-drug resistance proteins (MDR) or (ii) competition between fusidic acid and statins for hepatic glucuronidation.
Active statin forms are transported from blood by the OATP1B1 at the sinusoidal membrane into the liver where they inhibit HMG-Co A reductase. BCRP and MDR1 (also known as P-glycoprotein) are other transport proteins responsible for statin elimination from the hepatocytes into the bile [48] . Recent studies have shown that fusidic acid is a potent inhibitor of OATP1B1 [39, 47] and an inhibitor of BCRP [39] and MDR1 [47] . Thereby, fusidic acid has the possibility to increase statin systemic concentrations and risk of toxicity in other organs (musculoskeletal). Moreover, the acid forms of simvastatin and atorvastatin undergo a hepatic glucuronidation by UDP glucuronyl transferase (UGT) 1A1 and UGT1A3 [49] . Fusidic acid seems to undergo a hepatic glucuronidation by UGT1A1 [39] , but whether fusidic acid can, like gemfibrozil [50], inhibit this enzyme, is not clear at this time.
Taken together, these data provide evidence for molecular mechanisms that may explain the occurrence of rhabdomyolysis when fusidic acid is administered with statins. The long duration of treatment before rhabdomyolysis occurrence seems unique to fusidic acid and argues not to administer statins when a long treatment by fusidic acid is required. Owing to the large worldwide use of statins and the high rate of fatality associated with this co-administration, another antibiotic should be used and, if fusidic acid is absolutely necessary, the statin should be discontinued during antibiotic treatment and up to 7 days after fusidic acid discontinuation [11] . Rarely will interruption of this sort have adverse consequences for the patient [36] . Statins are now available over-the-counter in some countries, making the prevention of co-administration more difficult. Thus, it is not only the prescribers that should be informed of the risk of this combination but also the pharmacists and, most importantly, the patients.
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